Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-20 |
2024-03 |
0 |
N/A |
N/A |
N/A |
2024-04-01 |
2023-12 |
0 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-0.26 |
N/A |
N/A |
N/A |
2023-08-10 |
2023-06 |
-0.29 |
N/A |
N/A |
N/A |
2023-05-15 |
2023-03 |
-0.27 |
N/A |
N/A |
N/A |
2023-03-16 |
2022-12 |
-0.27 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-10-11 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-10 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-13 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-06-05 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-24 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-05-15 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2019-09-17 |
683 CAPITAL MANAGEMENT L L C |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2019-09-22 |
ARMISTICE CAPITAL L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2016-07-28 |
BIENEN HENRY S |
Director |
8.91K |
Conversion of Exercise of derivative security |
2016-07-28 |
FRUCHTMAN STEVEN M |
Officer |
6.38K |
Conversion of Exercise of derivative security |
2016-07-28 |
GUERIN MARK PATRICK |
Officer |
3.73K |
Conversion of Exercise of derivative security |
2020-08-26 |
HOFFMAN MICHAEL B |
Director |
0.00 |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
708.62K |
836.17K |
3.38% |
2023-06-29 |
Blackrock Inc. |
248.88K |
293.68K |
1.19% |
2023-06-29 |
Renaissance Technologies, LLC |
234.67K |
276.92K |
1.12% |
2023-06-29 |
Geode Capital Management, LLC |
169.50K |
200.01K |
0.81% |
2023-06-29 |
Two Sigma Investments, LP |
157.80K |
186.20K |
0.75% |
2023-06-29 |
Two Sigma Advisers, LP |
143.34K |
169.14K |
0.68% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
365.66K |
431.48K |
1.74% |
2023-06-29 |
Vanguard Extended Market Index Fund |
321.97K |
379.92K |
1.53% |
2023-05-30 |
Fidelity Extended Market Index Fund |
81.91K |
95.84K |
0.39% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
33.20K |
38.84K |
0.16% |
2023-05-30 |
Fidelity Total Market Index Fund |
23.17K |
27.11K |
0.11% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
21.11K |
24.70K |
0.10% |
Split |
Date |
1 : 15 |
2021-05-21 |
1 : 15 |
2018-09-26 |
1 : 10 |
2016-06-01 |
1 : 10 |
2016-05-31 |